|
Company (Location) |
Company (Location) |
Value (M) |
Type/Product Area |
Terms/Details (Date) |
|
|
||||
|
I. Modified Agreements |
||||
|
October |
||||
|
Cortex Pharmaceuticals Inc. (Irvine, Calif.) |
Servier (Paris) |
$2 |
Servier will pay $2M, plus royalties and milestones to exercise its option to obtain the remaining rights to their jointly discovered high impact Ampakine compound CX1632/S47445 for memory and cognitive impairment in patients with Alzheimer's disease and other disorders |
Servier now has exclusive rights to develop and market the compound worldwide (10/7) |
|
Dynavax Technologies Corp. (Berkeley, Calif.) |
AstraZeneca plc (London) |
$143 |
Amended the 2006 collaboration to accelerate the initiation of clinical development of AZD 1419 for asthma |
Dynavax will manage early clinical development, with AstraZeneca providing about $20M to cover the cost of clinical development activities through Phase IIa; if AstraZeneca continues development, Dynavax will receive a $20M milestone payment and it could receive $100M in additional milestones, plus royalties; it will receive $3M to begin the clinical program (10/6) |
|
Dynavax Technologies Corp. (Berkeley, Calif.) |
GlaxoSmithKline plc (London) |
$203 |
Expanded its Toll-like receptor inhibitor collaboration with GSK to include a new target, TLR8 |
Dynavax will receive a $3M milestone payment and could be entitled to about $200M in milestones over the term of the alliance (10/24) |
|
Labopharm Inc. (Laval, Quebec) |
Gruppo Angelini SpA (Rome) |
ND |
Restructured the 2010 partnership such that Angelini will have an exclusive license and rights related to Oleptro in the U.S., Canada and other countries |
It gains the rights in exchange for 5% royalties on product sales in excess of $10M each quarter, plus additional royalties in other territories (10/6) |
|
November |
||||
|
Ablynx NV (Ghent, Belgium) |
Merck Serono (Geneva) |
$47.5 |
Expanded its relationship entering a third agreement to co-discover and co-develop Nanobodies against two targets in osteoarthritis |
Ablynx will receive an up-front payment of €20M ($27.1M), payable in two tranches over the next three months, and will be entittled to receive a further €15M ($20.4M) for each preclinical package accepted by Merck (11/10) |
|
Aileron Therapeutics (Cambridge, Mass.) |
Roche Holdings AG (Basel, Switzerland) |
ND |
Expanded collaboration to develop and commercialize stapled peptide drugs in the area of inflammatory disease |
The $1.1B drug development collaboration was launched in August 2010, and encompassed up to five programs of strategic importance to Roche (11/17) |
|
Tranzyme Pharma Inc. (Research Triangle Park, N.C.) |
Bristol-Myers Squibb Co. (Princeton, N.J.) |
ND |
Expanded deal to discover new macrocyclic drug candidates |
The deal struck in 2009 is extended to June 2012 (11/9) |
|
I. Terminated Agreements |
||||
|
October |
||||
|
Mymetics Corp. (Epalinges, Switzerland) |
Abbott (Abbott Park, Ill.) |
ND |
Mymetics regained its intranasal influenza vaccine from Solvay Pharma-ceuticals Inc., now part of Abbott |
Solvay suspended development after a change in strategy and reprioritization following the company's sale to Abbott (10/5) |
|
Newron Pharmaceuticals SpA (Milan, Italy) |
Merck Serono SA (Darmstadt, Germany) |
ND |
Merck exited the partnership with Newron on the Parkinson's drug safinamide |
Merck said it believes that safinamide has a more limited market potential than originally anticipated (10/24) |
|
November |
||||
|
Ablynx NV (Ghent, Belgium) |
Pfizer Inc. (New York) |
ND |
Terminated alliance on the development of nanobodies targeting tumor necrosis factor alpha |
Pfizer is handing back rights to ATN-103, which has completed two Phase II trials in rheumatoid arthritis, and a backup compound PF-05230905; Ablynx plans to find another partner (11/7) |
|
Amylin Pharmaceuticals Inc. (San Diego) |
Eli Lilly and Co. (Indianapolis) |
ND |
Terminated collaboration on diabetes drug exenatide |
The decision follows a legal battle in which Amylin lost a preliminary bid to block Lilly from promoting Tradjenta with the same sales force that markets exenatide drugs Byetta and Bydrueon (11/9) |
|
Furiex Pharmaceuticals Inc. (Morrisville, N.C.) |
Janssen Pharmaceutica NV (Beerse, Belgium) |
ND |
Janssen did not exercise its option to continue developing MuDelta, so Furiex acquired full exclusive license rights |
Furiex will owe payments to Janssen based on Phase III trial initiation, future regulatory milestones and sales milestones and royalties (11/3) |
|
|
||||
|
Notes: The date indicated refers to the BioWorld Today issue in which the news item can be found. ** Denotes the date the item ran in BioWorld International. |
||||